Moleculin Biotech (NASDAQ:MBRX) Now Covered by StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the stock.

Separately, Maxim Group downgraded shares of Moleculin Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th.

Moleculin Biotech Stock Down 16.4 %

Shares of NASDAQ MBRX opened at $1.07 on Tuesday. Moleculin Biotech has a one year low of $0.40 and a one year high of $10.35. The business’s fifty day moving average price is $1.61 and its 200-day moving average price is $2.20.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.